Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 211 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Contraceptive Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

NCT04018274
View directory record Official record
Conditions
Healthy
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Phase 3 Interventional Results available

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

NCT05264506
View directory record Official record
Conditions
Contraception
Interventions
NOMAC-E2 COC
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
14 Years to 35 Years · Female only
Enrollment
3,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

NCT00775190
View directory record Official record
Conditions
Contraception
Interventions
ortho tricyclen, Trinessa
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Adolescent Adherence to Hormonal Contraception

NCT00584038
View directory record Official record
Conditions
Contraception
Interventions
educational instruction and phone follow-up, educational instruction in clinic
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
1,155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives in the Metabolic Syndrome

NCT00205504
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance, Obesity, Cardiovascular Diseases
Interventions
Ortho Tri Cyclen
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

NCT00544882
View directory record Official record
Conditions
Healthy
Interventions
DR-1021, Mircette®, Kariva®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Lawrenceville, New Jersey • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

NCT06310616
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Loestrin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

NCT02792517
View directory record Official record
Conditions
Headache, Migraine
Interventions
Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Anaheim, California • Cypress, California • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Safety and Efficacy of an Oral Contraceptive

NCT00932321
View directory record Official record
Conditions
Prevention of Pregnancy
Interventions
Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

NCT02480881
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Oral Contraceptive, Loestrin 1.5/30
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
View directory record Official record
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 21, 2026, 9:58 PM EDT
Withdrawn Phase 4 Interventional

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

NCT01941134
View directory record Official record
Conditions
Bariatric Surgery Candidate, Contraception
Interventions
ethinyl estradiol-levonorgestrel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

NCT00996580
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
DR-103
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
3,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
94
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Phase 4 Interventional Results available

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

NCT01963403
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions
EE 30mcg/LNG 150mcg, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Sacramento, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 21, 2026, 9:58 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Assessing the Impact of Contraceptives on Bone Health Using 41Ca

NCT02367846
View directory record Official record
Conditions
Other Disorders of Bone Development and Growth
Interventions
Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)

NCT00682890
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS, Insulin Sensitivity
Interventions
placebo, metformin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

NCT03451110
View directory record Official record
Conditions
Healthy Subjects
Interventions
lemborexant, Loestrin, famotidine, fluconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 21, 2026, 9:58 PM EDT
Completed No phase listed Observational Results available

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

NCT01953211
View directory record Official record
Conditions
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Interventions
combined oral contraceptives
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 21, 2026, 9:58 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

NCT03296098
View directory record Official record
Conditions
Contraception, Healthy Female
Interventions
Ulipristal acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Effects of Oral Contraceptive Pills Versus Metformin

NCT03229057
View directory record Official record
Conditions
PCOS
Interventions
OCP + Metformin, OCP + Placebo, Metformin + Placebo
Drug
Lead sponsor
Anuja Dokras
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262740
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 21, 2026, 9:58 PM EDT